Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen

被引:17
作者
Wang, CH
Yeung, F
Liu, PC
Attar, RM
Geng, JP
Chung, LWK
Gottardis, M
Kao, CH
机构
[1] Indiana Univ, Dept Urol, Indianapolis, IN 46202 USA
[2] Kaohsiung Med Univ, Orthoped Res Ctr, Kaohsiung 807, Taiwan
[3] Kaohsiung Med Univ, Dept Biol, Kaohsiung 807, Taiwan
[4] Bristol Myers Squibb Co, Dept Oncol, Princeton, NJ 08543 USA
[5] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA
[6] Emory Univ, Dept Urol, Atlanta, GA 30322 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
关键词
D O I
10.1074/jbc.M207862200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate-specific antigen (PSA) is the most valuable marker for the evaluation of prostate cancer progression. The expression of PSA is controlled by androgen receptor (AR) through its binding to androgen-response elements (AREs). Several AREs have been identified within the 5.8-kb PSA promoter. The main activity of this 5.8-kb PSA promoter resides in a 455-bp enhancer core region located about 4 kb upstream of the TATA box. Our study suggests that in addition to the four AREs identified in the PSA enhancer core, another regulatory element (GAGATA), which is located at the region designated PSA3.1, also contributes to transcriptional regulation by androgens. Furthermore, electrophoretic mobility shift assay revealed that a putative transcriptional factor bound the GAGATA sequence in the PSA-producing prostate cancer cell. Further studies demonstrated that GAGATA factor preferentially bound the (G/C)(A/C/T)GATA sequence. The replacement of ATA with GGG in the GAGATA sequence completely eliminated the androgen-mediated transcriptional activity of the enhancer core. By using DNA-coupled magnetic beads and the Southwestern method, a 56-60-kDa protein was identified as the putative GAGATA binding factor. EMSA and Western blotting assay suggested that AR is not involved in androgen-mediated activation through PSA3.1. Therefore, we propose that binding of the GAGATA binding factor and AR to GAGATA and AREs, respectively, of the PSA enhancer core are required for the maximum transcriptional response to androgens.
引用
收藏
页码:32423 / 32430
页数:8
相关论文
共 31 条
  • [1] ABMAYR SM, 1993, CURRENT PROTOCOLS MO
  • [2] THE STRINGENCY AND MAGNITUDE OF ANDROGEN-SPECIFIC GENE ACTIVATION ARE COMBINATORIAL FUNCTIONS OF RECEPTOR AND NONRECEPTOR BINDING-SITE SEQUENCES
    ADLER, AJ
    SCHELLER, A
    ROBINS, DM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (10) : 6326 - 6335
  • [3] Bhayani S B, 1999, Semin Urol Oncol, V17, P148
  • [4] The enhanceosome and transcriptional synergy
    Carey, M
    [J]. CELL, 1998, 92 (01) : 5 - 8
  • [5] Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer
    Castaldo, G
    Cecere, G
    diFusco, V
    Prezioso, D
    dArmiento, M
    Salvatore, F
    [J]. CLINICA CHIMICA ACTA, 1997, 265 (01) : 65 - 76
  • [6] GATA transcription factors and cardiac development
    Charron, F
    Nemer, M
    [J]. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 1999, 10 (01) : 85 - 91
  • [7] Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
    Cleutjens, KBJM
    vanEekelen, CCEM
    vanderKorput, HAGM
    Brinkmann, AO
    Trapman, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) : 6379 - 6388
  • [8] A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans
    Cleutjens, KBJM
    vanderKorput, HAGM
    EhrenvanEekelen, CC
    Sikes, RA
    Fasciana, C
    Chung, LW
    Trapman, J
    [J]. MOLECULAR ENDOCRINOLOGY, 1997, 11 (09) : 1256 - 1265
  • [9] DEVOS P, 1991, J BIOL CHEM, V266, P3439
  • [10] PROSTATE-SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN - 2 KALLIKREINS OF THE HUMAN PROSTATE
    HENTTU, P
    VIHKO, P
    [J]. ANNALS OF MEDICINE, 1994, 26 (03) : 157 - 164